NCT05057806View on ClinicalTrials.gov

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

November 30, 2026

Study Completion Date

March 31, 2027

Conditions
Type2 DiabetesHeart Failure With Preserved Ejection Fraction
Interventions
DRUG

Empagliflozin 25 MG

Empagliflozin 25MG will be administered orally once per day for 3 months

DRUG

Placebo

The placebo will be administered orally once per day for 3 months

Trial Locations (2)

78207

RECRUITING

Texas Diabetes Institute - University Health System, San Antonio

78229

RECRUITING

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

Doris Duke Charitable Foundation

OTHER

collaborator

Max and Minnie Tomerlin Voelcker Fund

UNKNOWN

lead

The University of Texas Health Science Center at San Antonio

OTHER